Soft Tissue Repair Products was Sanara MedTech’s largest product and service line in fiscal 2025, bringing in $91.35M of $103.12M (89%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Soft Tissue Repair Products | $41.65M | $54.84M | $76.13M | $91.35M | |||
| Sanara Legacy Product Sales | — | — | — | — | |||
| Product Sales Revenue | — | — | — | — | |||
| Bone Fusion Products | $3.99M | $9.95M | $10.55M | $11.77M | |||
| Royalty | $201.00K | $201.00K | — | — | |||
| Royalty Revenue | — | — | — | — | |||
| Total | $45.84M | $64.99M | $86.67M | $103.12M |
Sanara MedTech brought in $103.12M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 19.0% from $86.67M in fiscal 2024. Soft Tissue Repair Products was the largest at $91.35M (88.6%), ahead of Bone Fusion Products at $11.77M (11.4%).
Compared with fiscal 2024, Soft Tissue Repair Products grew 20.0% to $91.35M and Bone Fusion Products grew 11.6% to $11.77M.
Sanara MedTech stopped reporting Royalty as a separate line after fiscal 2023, when it brought in $201.00K.
Sanara Surgical was Sanara MedTech’s largest segment in fiscal 2023, bringing in $64.99M of $64.99M (100%).
| Segment | FY 2023 |
|---|---|
| Sanara Surgical | $64.99M |
| Thp | $2.73K |
| Total | $64.99M |
Sanara MedTech brought in $64.99M from its two segments in fiscal 2023, the year ended December 31, 2023. Sanara Surgical was the largest at $64.99M (100.0%), ahead of Thp at $2.73K (0.0%).
Sanara MedTech (SMTI) reports its revenue by product and service and by segment. In fiscal 2025, Soft Tissue Repair Products was its largest product and service line, bringing in $91.35M (88.6% of the total), followed by Bone Fusion Products at $11.77M (11.4%).
Soft Tissue Repair Products was Sanara MedTech's largest product and service line in fiscal 2025, bringing in $91.35M, or 88.6% of the $103.12M total across its two product and service lines.
Sanara Surgical was Sanara MedTech's largest segment in fiscal 2023, bringing in $64.99M, or 100.0% of the $64.99M total across its two segments.
Soft Tissue Repair Products grew faster than Bone Fusion Products in fiscal 2025, up 20.0% from $76.13M to $91.35M. Bone Fusion Products grew 11.6% to $11.77M.
Every figure comes from Sanara MedTech's annual financial filings, as reported. Each line keeps the name Sanara MedTech gives it, and years follow its fiscal calendar.
Sanara MedTech's revenue by product and service goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.